Global Sexually Transmitted Diseases Testing Market Report and Forecast 2024-2032

Global Sexually Transmitted Diseases Testing Market Outlook

The global sexually transmitted diseases testing market size reached a value of approximately USD 102.52 billion in 2023. The market is expected to grow at a CAGR of 5.80% between 2024 and 2032, reaching a value of around USD 169.90 billion by 2032.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Key Trends in the Market

Sexually transmitted diseases or STDs, also known as venereal diseases, refer to viral, bacterial, and parasitic diseases that are spread by sexual contact. Initial transmission typically takes place in the form of a sexually transmitted infection or STI that later becomes a disease or STD. In initial stages, the disease may be asymptomatic. Sexually transmitted diseases testing refers to the testing processes, procedures, and devices used to identify the presence of an STD and perform diagnostics. STDs may also be spread through non-sexual means, such as sharing of needles, blood transfusions, or from mothers to children during childbirth or pregnancy. 

• Over the past few years, STD prevalence and incidence have significantly increased. As the number of cases increases, nations all over the world are focusing on developing national screening programmes to expand the use of testing for sexually transmitted diseases. Policies for funding of diagnostic tests for sexually transmitted diseases have also been helpful. These factors have a significant impact on the growth of the global sexually transmitted disease testing market.

• Increase in initiatives and campaigns by various governments, and rising public awareness of various sexually transmitted diseases are increasing the demand for STD tests and the sexually transmitted diseases testing market. With a growing population of people that are sexually active, more people are opting for regular testing for STDs to protect themselves and partners.

• The development of more advanced testing devices and improvements in treatment strategies are anticipated to increase demand for testing of sexually transmitted diseases and the sexually transmitted diseases (STDs) testing devices market. Availability of novel diagnostics and advancements in testing service infrastructure are resulting in faster and more precise test results, enabling improved treatment of STDs.

Global Sexually Transmitted Diseases Testing Market Analysis

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Based on disease type, the market is divided into chlamydia, gonorrhoea, herpes simplex virus, syphilis, and human papillomavirus (HPV), among others. The sexually transmitted diseases testing market on the basis of device type is bifurcated into laboratory devices and point of care (POC) devices. Laboratory devices are further segmented into thermal cyclers- PCR, lateral flow readers, flow cytometers, differential light scattering machines, and absorbance microplate reader, among others, while point of care (POC) devices are sub-divided into phone chips (Microfluidics and ICT) and portable/bench top/rapid diagnostic. The regional markets for sexually transmitted diseases testing are divided into North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa. 

The comprehensive EMR report provides an in-depth assessment of the market based on the Porter's five forces model along with giving a SWOT analysis. The report gives a detailed analysis of the following key players in the global sexually transmitted diseases testing market, covering their competitive landscape and the latest developments like mergers, acquisitions, investments, and expansion plans. 

• F. Hoffmann-La Roche Ltd

• Abbott Laboratories

• bioMérieux SA

• Thermo Fisher Scientific Inc.

• Quidel Corporation

• Hologic, Inc.

• Bio-Rad Laboratories, Inc.

• DiaSorin S.p.A

• QIAGEN GmbH

• Becton, Dickinson and Company

• Others

Market Share by Disease Type

Gonorrhoea is predicted to account for a sizable share of the sexually transmitted diseases testing market during the forecast period. An infection caused by a bacterium, gonorrhoea is one of the most widely prevalent STDs that can be contracted during oral, anal, or vaginal sex with an infected patient. Both men and women can get sick from the infection. In the upcoming years, the market share for gonorrhoea testing will increase due to the rising prevalence of the infection. 

Testing for gonorrhoea is crucial because it identifies the existence of the gonorrhoea bacteria in the body so that an effective therapy can be prescribed quickly. Lack of awareness about sexually transmitted diseases and a preference for unprotected sex are increasing the prevalence of gonorrhoea and other STDs, increasing the growth of the sexually transmitted diseases testing market. 

Market Share by Region

North America is predicted to dominate the global sexually transmitted diseases testing market due to the rising demand for sexually transmitted diseases diagnostics, accessibility of technologically advanced products, and increasing uptake of point of care testing. The United States is projected to be a key market in the North American region because of the presence of numerous diagnostic firms and increased awareness about STDs among people. 

Meanwhile, in the Asia Pacific an increase in STD cases, a growing youth population, lack of awareness, and increasing activities by various governments are driving the Asia Pacific sexually transmitted diseases (std) testing market. Surging initiatives of various governments and greater patient awareness through education campaigns are anticipated to fuel the expansion of the market for sexually transmitted diseases testing in the Asia Pacific in the coming years.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Competitive Landscape

F. Hoffmann-La Roche Ltd, founded in 1896 and headquartered in Switzerland is a leading biotech company in the world that provides accurate medications with over 50% of their product pipeline comprising of biopharmaceuticals. The products and services of the company address disease prevention, diagnostics, and treatment to enhance patient wellbeing and quality of life. Their diagnostic specialties include coagulation testing, tissue/haematology/urine diagnostics, and diabetes.

Abbott Laboratories is a leader in worldwide healthcare headquartered in Illinois in the United States. With top brands and products in diagnostics, medical equipment, nutrition, and generic medications, its portfolio of game-changing technology covers the whole range of healthcare. The company, which was established in 1888, is renowned for its diagnostics, medical equipment, food products, and branded generic medications.

Thermo Fisher Scientific Inc., with its headquarters in Massachusetts, United States, is a pioneer in the field of science and healthcare. Thermo Fisher Scientific, established in 1956, equips its customers to make the world a safer, cleaner, and healthier place. To address challenging analytical challenges in research, diagnostics, and clinical laboratories, the company offers medical equipment, reagents and consumables, software, and services, and analytical instruments.

Other market players include bioMérieux SA, Quidel Corporation, Hologic, Inc., Bio-Rad Laboratories, Inc., DiaSorin S.p.A, QIAGEN GmbH, and Becton, Dickinson and Company, among others.

Key Highlights of the Report